Delivery Order N6817123D2003-N6817124F2027

<p>This is a Firm Fixed Price delivery order contract awarded by the Defense Health Agency to Immucor Italia S.P.A., a for-profit organization, for the PANOSCREEN I, II, and III products. The contract has a potential value of $7,639.72 and a completion date of October 27, 2023. The contract is not associated with a set-aside program.</p>

The Defense Health Agency awarded a $12,248.86 delivery order to Immucor Italia S.P.A. on May 29, 2024, for PANOSCREEN I, II, and III medical screening equipment, with performance in Italy and completion targeted for December 29, 2024. This delivery order is structured as a firm fixed-price contract with no set-aside designation, meaning the award was made through full and open competition. The delivery order is issued under Immucor Italia S.P.A.'s parent Indefinite Delivery Contract with the...

The U.S. Defense Health Agency (DHA) has awarded a firm fixed-price delivery order to Immucor Italia S.P.A., a for-profit organization, for the provision of PANOSCREEN I, II, and III medical screening equipment. This $6,975.76 contract is part of a larger Indefinite Delivery Contract (IDC) awarded to Immucor Italia S.P.A. on June 13, 2023, with a ceiling value of $138,594.60 and an ultimate completion date of June 12, 2028. The DHA's award of this delivery order, which has no set-aside...

This is a firm fixed-price purchase order awarded by the Defense Health Agency to Immucor Inc., a for-profit manufacturer, for the delivery of medical supplies such as fetal blood screen kits, blood cells, and PanoCell products. The potential value of the contract is $216,898.69, with a performance period through April 24, 2023. The contract does not have a set-aside designation. Immucor has previously been awarded federal contracts to provide blood banking supplies, reagents, and testing...

This federal contract award is for a yearly standing order for PANOCELL-20 20X3 and FMH RAPIDSCREEN KITS placed by the Bureau of Medicine and Surgery, a defense agency, with the prime contractor Immucor Inc. The $10,671.69 firm fixed price purchase order has a completion date of September 30, 2017. There is no set-aside designation for this award. Immucor Inc. is a manufacturer of in vitro diagnostic products, reagents, and blood banking equipment, and has a history of providing supplies and...

This is a firm-fixed price purchase order contract awarded by the Defense Health Agency to Immucor Inc., a for-profit manufacturer of in vitro diagnostics, reagents, and blood banking supplies. The $514,572.15 contract is for the delivery of unspecified supplies, with a period of performance ending on September 30, 2023. No set-aside designation was used. Immucor is an experienced federal contractor, having previously provided a variety of medical products and services to agencies such as the...

This is a delivery order contract awarded by the Defense Health Agency to Immucor Inc., a for-profit manufacturer of in vitro diagnostic products, reagents, and equipment for blood transfusion and transplantation compatibility testing. The contract is for the supply of PANOCELL I, II, III (3X10ML) medical products, with a ceiling value of $153,884.39 and a period of performance through September 30, 2021. The contract was awarded on a firm fixed-price basis without any set-aside designation....

This is a firm fixed-price purchase order awarded by the Bureau of Medicine and Surgery, a defense agency, to Immucor Inc. for the yearly supply of PANOCELL-20 and FMH RAPID SCREEN diagnostic products. The award is valued at $9,931.60 and does not have a set-aside designation. Immucor is a manufacturer of in vitro diagnostics, reagents, and equipment for blood transfusion and transplantation compatibility testing. The company has held multiple federal contracts to provide specialized medical...

This firm fixed-price federal contract award to Immucor Inc. is for the provision of in-vitro diagnostic substances and related manufacturing services. The $20,000.00 contract was issued by the Defense Health Agency (DHA), a component of the Department of Defense, and has an ultimate completion date of September 30, 2022. The award does not have a set-aside designation. Immucor Inc. is a for-profit manufacturer specializing in automated blood testing equipment, reagents, and consumables for...

Immucor Inc. was awarded a firm fixed price blanket purchase agreement (BPA) call contract by the Defense Health Agency on October 18, 2023. The contract has a potential value of $18,287.55 and requires delivery of Rapid Screen, Complement Control Cells, Panocell 20, and Immucor reagents by October 17, 2024 at Fort Belvoir, Virginia. No set-aside designation was used for this award to support the Defense Health Agency's medical products procurement programs. Immucor Inc. will serve as the...